Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Bariatric Embolization Could Promote Weight Loss

By HospiMedica International staff writers
Posted on 13 Dec 2015
An experimental percutaneous procedure which involves embolization of the left gastric artery can lead to 50% reductions in excess weight, according to a new study. More...


Researchers at Dayton Interventional Radiology (OH, USA) performed the percutaneous procedure—dubbed bariatric or gastric artery embolization—using Bead Block, a formulation of tiny polyvinyl alcohol hydrogel microspheres that is made by Infiniti Medical (Menlo Park, CA, USA). The microspheres are tinted blue to improve visualization and come in a variety of sizes and preloaded syringes to facilitate targeted embolization of tumors and vascular malformations. Prior to use, Bead Block is mixed with an iodinated contrast agent and injected under fluoroscopic guidance.

The results showed that following embolization, one patient underwent a weight loss of nearly 20 kg (48.6% of her excess body weight); another patient, who was a diabetic, lost 12 kg (17% of her excess body weight) after the procedure, and a third lost 5 kg. A fourth patient lost only two and a half kilograms, but according to the researchers suffered a depressive event during the trial, and may have overeaten to compensate. The study was presented at the Radiological Society of North America (RSNA) annual meeting, held during November–December 2015 in Chicago (IL, USA).

“Bariatric embolization is a promising treatment for obesity. It can be performed on an outpatient basis and has the potential to provide as much weight loss as is seen in gastric surgery,” said lead author and study presenter Mubin Syed, MD. He added that the researchers believe that gastric artery embolization reduces ghrelin—the “hunger hormone”—and that embolization of the left gastric artery does not appear to harm the stomach because the organ has a rich collateral blood supply.

The experimental percutaneous procedure was conducted in four morbidly obese patients under a US Food and Drug Administration (FDA) experimental device exemption to determine if the larger Gastric Artery Embolization Trial for Lessening Appetite Nonsurgically (GETLEAN) study, which is currently recruiting, should be expanded. The pilot study will enroll morbidly obese patients with a body mass index (BMI) higher than 40 kg/m2 who are otherwise healthy. Patients must also have failed previous attempts at weight loss through diet, exercise, and behavior modification.

Related Links:

Dayton Interventional Radiology
Infiniti Medical



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.